METTL3 and neoplasm: Although BT remains an experimental compound, CUB is a natural product already approved by the Chinese Food and Drug Administration,52 and additional agents aimed at RBP pathways—such as METTL3 inhibitors already advancing into clinical trials (NCT05584111)57—may likewise help reinvigorate anti-tumor immunity.